- Home
- SCS vs DAWN Comparison
SCS vs DAWN Comparison
Compare SCS & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCS
- DAWN
- Stock Information
- Founded
- SCS 1912
- DAWN 2018
- Country
- SCS United States
- DAWN United States
- Employees
- SCS N/A
- DAWN N/A
- Industry
- SCS Office Equipment/Supplies/Services
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- SCS Consumer Discretionary
- DAWN Health Care
- Exchange
- SCS Nasdaq
- DAWN Nasdaq
- Market Cap
- SCS 1.6B
- DAWN 1.3B
- IPO Year
- SCS 1998
- DAWN 2021
- Fundamental
- Price
- SCS $11.70
- DAWN $12.54
- Analyst Decision
- SCS Strong Buy
- DAWN Strong Buy
- Analyst Count
- SCS 2
- DAWN 7
- Target Price
- SCS $17.00
- DAWN $36.33
- AVG Volume (30 Days)
- SCS 694.5K
- DAWN 1.2M
- Earning Date
- SCS 12-18-2024
- DAWN 02-24-2025
- Dividend Yield
- SCS 3.42%
- DAWN N/A
- EPS Growth
- SCS 52.41
- DAWN N/A
- EPS
- SCS 0.96
- DAWN N/A
- Revenue
- SCS $3,153,200,000.00
- DAWN $101,953,000.00
- Revenue This Year
- SCS $0.99
- DAWN N/A
- Revenue Next Year
- SCS $2.19
- DAWN $35.22
- P/E Ratio
- SCS $12.18
- DAWN N/A
- Revenue Growth
- SCS N/A
- DAWN N/A
- 52 Week Low
- SCS $10.90
- DAWN $11.13
- 52 Week High
- SCS $14.74
- DAWN $18.07
- Technical
- Relative Strength Index (RSI)
- SCS 45.31
- DAWN 49.68
- Support Level
- SCS $10.90
- DAWN $11.13
- Resistance Level
- SCS $11.67
- DAWN $13.30
- Average True Range (ATR)
- SCS 0.28
- DAWN 0.51
- MACD
- SCS 0.06
- DAWN 0.05
- Stochastic Oscillator
- SCS 69.74
- DAWN 64.98
About SCS Steelcase Inc.
Steelcase Inc is a furniture company based in the United States. Its brands such as Steelcase, AMQ, Coalesse, Designtex, and others offer a portfolio of furniture and architectural products and services designed to help customers create workplaces. It markets its products and services to businesses and organizations predominantly through a network of dealers and also sells to consumers in markets around the world through web-based and retail distribution channels. The company's reportable segments include the Americas which generates key revenue, and International.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.